Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Community study demonstrates Keppra’s use in various pain types

21.03.2003


New data shows that the antiepileptic drug Keppra (levetiracetam), when used alone and in combination with other treatments, provided relief to more than 90 percent of patients with a range of pain syndromes, from migraine headaches to neck and back pain. The study of 400 patients, conducted by the Statesville Pain Associates of Statesville, N.C., was presented today at the American Pain Society’s 22nd Annual Scientific Meeting.



"To date, studies of Keppra to treat pain have been conducted in small patient populations only. Our study of hundreds of patients showed that Keppra was well tolerated and has the potential to be an effective pain treatment alone or in combination with gabapentin, the current ’gold standard’ for the treatment of neuropathic pain," said Douglas Pritchard, M.D., pain specialist and lead investigator of the study. "As pain specialists, we’re always searching for more treatment options. It’s been encouraging to see this response to treatment in such a wide variety of pain states."

Each year chronic pain affects 70 million Americans, or approximately one in every four people, and contributes to 40 million doctor visits. The burden of pain also results in 515 million lost workdays, and accounts for $100 billion in medical expenses each year.1


Investigators determined that 372 of 400 patients involved in the study responded to Keppra, currently approved by the U.S. Food and Drug Administration for the adjunctive treatment of partial onset seizures in adults. Keppra was given as a stand-alone treatment or in combination with gabapentin, another antiepileptic drug (AED) used to treat pain, to 400 patients experiencing migraine headaches, neck, back, nerve, diabetic and complex regional pain syndromes.

This retrospective analysis was of 400 patients given Keppra over a six-month period as a stand-alone drug (n=30%) and in combination with gabapentin (n=70%). Five percent of the patients in this study were treated for migraine headaches and the others were treated for various types of pain including, neck pain (20%), back pain (40%), nerve pain (15%), diabetic pain (15%) and complex regional pain syndromes (5%). Keppra was titrated to dosages between 1,000 and 2,000 mg/day, throughout the duration of treatment (one to six months).

Participants also evaluated their own pain using the visual analog scale (VAS), in which pain is evaluated on a scale of 0-10, with 10 signifying the highest degree of pain. Before starting treatment with Keppra, patients rated their pain between 7 and 10, but within five to 10 days, their self-evaluated VAS scores fell to 5 and 6. The patients’ pain relief was also evaluated by a patient global assessment of pain indicating good pain relief as well as improved function and quality of life.

The most common side effects associated with the use of Keppra in this analysis were drowsiness and nausea.


About Statesville Pain Associates
The pain management team at Statesville Pain Associates strives to minimize patients’ pain, restore their ability to function and ultimately enable them to enjoy a better quality of life. Headed by Dr. Douglas Pritchard and Dr. Bobby Kearney, Statesville Pain Associates treats over 800 patients a month using a multidimensional and a multidisciplinary approach.

Jessica Balaban | EurekAlert!
Further information:
http://www.ncps-cpr.com

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>